Substance / Medication

Lanreotide acetate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.
Chan Dennis S, Kanagaratnam Aran L, Pavlakis Nick et al. · J Neuroendocrinol · 2025
PMID: 37987535Meta-AnalysisFull text (PMC)
Endoscopic Ultrasound-Guided Fine Needle Acquisition for Evaluation of Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Ye Xiaohua, Hua Hongjun, Hu Chunxiao et al. · J Clin Gastroenterol · 2025
PMID: 39312536Meta-Analysis
Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms.
La Salvia Anna, Modica Roberta, Spada Francesca et al. · Endocrine · 2025
PMID: 39671148Meta-Analysis
Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate.
Teltayev Daniyar, Akshulakov Serik, Ryskeldiev Nurzhan et al. · Gynecol Endocrinol · 2017
PMID: 29264984Case Report
Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).
Modan-Moses Dalit, Koren Ilana, Mazor-Aronovitch Kineret et al. · J Clin Endocrinol Metab · 2011
PMID: 21697252Case Report
[Lanreotide acetate may cure cystic dystrophy in heterotopic pancreas of the duodenal wall].
Basili E, Allemand I, Ville E et al. · Gastroenterol Clin Biol · 2001
PMID: 11910994Case Report
An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E, Deshpande H A, Stein S M · Drugs Today (Barc) · 2018
PMID: 30209440Review
Lanreotide acetate subcutaneous injection-induced granulomatous inflammation after surgery for neuroendocrine tumor of unknown primary origin.
Saigusa Susumu, Sakurai Hiroyuki, Fujikawa Hiroyuki et al. · Int Cancer Conf J · 2026
PMID: 41589245OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lanreotide acetate (substance)
SNOMED CT
429611006
UMLS CUI
C0771414

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.